Royal Bank of Canada’s Surface Oncology, Inc. Common Stock SURF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-24,432
| Closed | -$21K | – | 7891 |
|
|
2023
Q2 | $21K | Buy |
24,432
+1,620
| +7% | +$1.16K | ﹤0.01% | 6199 |
|
|
2023
Q1 | $16K | Sell |
22,812
-473
| -2% | -$383 | ﹤0.01% | 6127 |
|
|
2022
Q4 | $19K | Sell |
23,285
-123,055
| -84% | -$121K | ﹤0.01% | 6336 |
|
|
2022
Q3 | $152K | Buy |
146,340
+13,841
| +10% | +$22.1K | ﹤0.01% | 4983 |
|
|
2022
Q2 | $218K | Buy |
132,499
+12,570
| +10% | +$26.1K | ﹤0.01% | 4752 |
|
|
2022
Q1 | $352K | Buy |
119,929
+8,578
| +8% | +$30.1K | ﹤0.01% | 4582 |
|
|
2021
Q4 | $533K | Buy |
111,351
+2,732
| +3% | +$17.6K | ﹤0.01% | 4392 |
|
|
2021
Q3 | $822K | Sell |
108,619
-2,840
| -3% | -$18.2K | ﹤0.01% | 3893 |
|
|
2021
Q2 | $831K | Buy |
111,459
+38,284
| +52% | +$295K | ﹤0.01% | 3824 |
|
|
2021
Q1 | $571K | Buy |
73,175
+30,800
| +73% | +$308K | ﹤0.01% | 4068 |
|
|
2020
Q4 | $392K | Buy |
42,375
+40,413
| +2,060% | +$351K | ﹤0.01% | 4340 |
|
|
2020
Q3 | $14K | Buy |
1,962
+1,506
| +330% | +$9.14K | ﹤0.01% | 5829 |
|
|
2020
Q2 | $3K | Hold |
456
| – | – | ﹤0.01% | 6223 |
|
|
2020
Q1 | $1K | Buy |
456
+324
| +245% | +$854 | ﹤0.01% | 6535 |
|
|
2019
Q4 | $0 | Buy |
+132
| New | +$220 | ﹤0.01% | 7227 |
|
|
2019
Q1 | – | Sell |
-70
| Closed | – | – | 7203 |
|
|
2018
Q4 | $0 | Sell |
70
-381
| -84% | -$2.94K | ﹤0.01% | 7258 |
|
|
2018
Q3 | $5K | Buy |
451
+405
| +880% | +$4.75K | ﹤0.01% | 6296 |
|
|
2018
Q2 | $1K | Buy |
+46
| New | +$666 | ﹤0.01% | 6414 |
|
Royal Bank of Canada's SURF Position: Q3 2023 in Review
Royal Bank of Canada sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2023, closing a stake of 24,432 shares — an estimated $21K sold.
Royal Bank of Canada first reported a position in SURF in Q2 2018 and held it in 18 quarters. The position peaked at $831K in Q2 2021. 0 funds tracked by Wall St. Rank hold SURF as of Q3 2023.
- Royal Bank of Canada reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Royal Bank of Canada sold 24,432 Surface Oncology, Inc. Common Stock shares in Q3 2023, an estimated $21K.
- Royal Bank of Canada first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 18 quarters.
- Royal Bank of Canada's Surface Oncology, Inc. Common Stock position peaked at $831K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2023.
Based on Royal Bank of Canada's 13F filing for Q3 2023, filed 14 Nov 2023.